Referred to the House Committee on Energy and Commerce.
The bill bars any Federal department, agency, or office from conducting, funding, approving, or otherwise supporting research using human fetal tissue obtained from an induced abortion. It preserves federal research on tissue from miscarriages or stillbirths under amended PHSA rules, permits development of non‑fetal-derived high-efficiency cell lines, and prohibits soliciting or knowingly accepting donations of fetal tissue when the pregnancy was deliberately initiated to provide tissue or the tissue came from an induced abortion.
Progressives stress public‑health and scientific harms from the ban.
Relative to its intended legislative type, this bill is a clear substantive policy statute that directly amends relevant provisions of the Public Health Service Act to prohibit federal involvement with human fetal tissue obtained by induced abortion.
The bill bars any Federal department, agency, or office from conducting, funding, approving, or otherwise supporting research using human fetal tissue obtained from an induced abortion.
It preserves federal research on tissue from miscarriages or stillbirths under amended PHSA rules, permits development of non‑fetal-derived high-efficiency cell lines, and prohibits soliciting or knowingly accepting donations of fetal tissue when the pregnancy was deliberately initiated to provide tissue or the tissue came from an induced abortion.
The bill also makes conforming statutory changes and repeals a prior NIH statutory provision related to fetal tissue research.
Content is ideologically salient and affects federal biomedical programs; narrow text helps sponsors but broader opposition and Senate hurdles lower chances.
Relative to its intended legislative type, this bill is a clear substantive policy statute that directly amends relevant provisions of the Public Health Service Act to prohibit federal involvement with human fetal tissue obtained by induced abortion. It specifies exceptions and alters statutory definitions, but provides limited administrative, fiscal, and enforcement detail.
Progressives stress public‑health and scientific harms from the ban.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives stress public‑health and scientific harms from the ban.
Likely to oppose the bill as an ideological restriction on federally supported biomedical research that could hinder public‑health and basic science.
Supporters' allowance for miscarriage/stillbirth tissue and alternative cell lines will be seen as insufficient to avoid real harms to certain research areas.
Views the bill as a policy balancing ethical concerns with research needs but worries about practical scientific consequences and cost.
Would seek specific safeguards, transition timelines, and funding for alternatives before backing it.
Likely to support the bill as protecting unborn life and preventing federal complicity in abortion‑derived tissue research.
Welcomes explicit prohibition and encouragement of ethical alternatives.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is ideologically salient and affects federal biomedical programs; narrow text helps sponsors but broader opposition and Senate hurdles lower chances.
The bill has not accumulated any surfaced votes yet.
Progressives stress public‑health and scientific harms from the ban.
Content is ideologically salient and affects federal biomedical programs; narrow text helps sponsors but broader opposition and Senate hurd…
Relative to its intended legislative type, this bill is a clear substantive policy statute that directly amends relevant provisions of the Public Health Service Act to prohibit federal involvement with human fetal tissu…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.